Royalty Report: Drugs, cardiac, implants – Collection: 275803

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • cardiac
  • implants
  • Cancer
  • Disease
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 275803

License Grant
Licensor hereby grants to Licensee and its Affiliates during the Term, with respect to the Field only, an exclusive, worldwide, royalty bearing license, with the right to grant sublicenses through multiple tiers of sublicenses, in, to, and under the Licensed Patents, Licensed Compounds, Licensed Know-How, Licensed Process, and Licensed Product to develop, distribute, market, make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Compounds, Licensed Processes, and Licensed Products. The parties hereto acknowledge that such license as described in the preceding sentence is not intended to apply to Licensed Patents, Licensed Compounds, Licensed Know-How, Licensed Process, and Licensed Product which is not related to the Field.
License Property
Licensed Product shall mean any products prepared, created, generated or synthesized by use of the Licensed Process having Licensed Compound(s) as a primary active ingredient or agent, including 4.4-dimethyl-benziso-(2H)-selenazine compounds and formulations thereof for use in the Field.

Licensed Patents shall mean any and all i) Patents covering the Licensed Compounds, Licensed Process, Licensed Know-How which have a Valid Claim; and ii) the Patents set forth which have a Valid Claim;
5968920 – Compounds having a benzisoselen-azoline and -azine structure, method for preparing same and therapeutic uses thereof
6093532 – Method for storing a biological organ transplant graft using a benzisoselen-azoline or -azine compound
5973009 – Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use

Licensed Compound shall mean a set of compounds having a benzolsoselenazoline and azine structure, and all derivatives, salts, enantiomers, crystal structures, metabolites, esters, and polymorphs, formulations and improvements thereof including a set of cyclic organoselenium compounds (each as disclosed in the Patents) for use in the Field.

Licensed Process shall mean synthetic routes, materials, conditions, and/or processes relating to and for the manufacture of the Licensed Compounds and/or Licensed Product relating to the Field.

Field of Use
Field shall mean any and all uses including but not limited to the therapeutic, diagnostic, preventative, amerliorative, and/or prognostic in Cardiovascular Indications, except for all drug eluting implanted devices.

Licensee has the rights to develop, manufacture, and market Licensor 's (oxidative stress diseases) Phase II BXT-51072 for cardiovascular indications including acute coronary syndromes, atherosclerosis, and stroke.

IPSCIO Record ID: 260439

License Grant
Licensor grants, with respect to the Field an exclusive, sole, worldwide license, with the right to grant sublicenses through multiple tiers of sublicenses, in, to, and under the Licensed Patents, Licensed Compounds, Licensed KnowHow, Licensed Process, and Licensed Product to develop, distribute, market, make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Compounds, Licensed Processes, and Licensed Products.
License Property
The patents include Novel compounds having a Benzoisoselen-azoline and -azine structure, method for preparating same and therapeutic uses thereof;   Aromatic Diselenides and Selenosulfides, their preparation and their uses, more particularly their therapeutical use;  and, Cyclic Organoselenium Compounds, their preparation and their uses.

The Licensed Compound shall mean a set of compounds having a benzoisoselenazoline and azine structure, and all derivatives, salts, enantiomers, crystal structures, metabolites, esters, and polymorphs, formulations and improvements thereof including a set of cyclic organoselenium compounds, each as disclosed and claimed in the Licensed Patents, for use in the Field.

The Licensed Process shall mean synthetic routes, materials, conditions, and/or processes relating to and for the manufacture of the Licensed Compounds and/or Licensed Product relating to the Field as disclosed in the Licensed Patents .

The Licensed Product shall mean any products prepared, created, generated or synthesized by use of the Licensed Process having Licensed Compound(s) as a primary active ingredient or agent which is disclosed and claimed in the Licensed Patents, including but not limited to BXT-51072, a licensed  compound, and the organoselenium compounds and formulations thereof disclosed and claimed in the Licensed Patents.

The new agreement expands the scope of a previous license to include non-cardiovascular indications.

Field of Use
The Field shall mean any and all uses including but not limited to the therapeutic, diagnostic, preventative, amerliorative, and/or prognostic for and in any indication, assay, disease and/or condition.

The patents cover a family of orally bioavailable organoselenium compounds that have shown anti-oxidant and anti-inflammatory properties in clinical and preclinical studies.

ALT-2074 (formerly BXT-51072), Licensee's lead compound under this license, is currently in a Phase 2 clinical study for cardiovascular indications.  By mimicking glutathione peroxidase (GPx), ALT-2074 may protect against excessive oxidation of lipids and thereby limit inflammation.  Licensee believes that the compound may be useful in patients with diabetes, whose cardiovascular disease may be caused by high levels of circulating oxidized lipids and associated inflammation.

IPSCIO Record ID: 289243

License Grant
The Licensor of Sweden grants an exclusive, worldwide license under the Licensed Licensor Patent Rights and Licensor Know-How to develop, make, use, import, export, offer for sale and sell, and to have developed, made, used, imported, exported, offered for sale and sold, the Licensed Products, with the right to grant sublicenses.
License Property
Licensor has developed the Compound as a therapeutic for the cardiovascular market.

The Compound means the Milano variant of Apolipoprotein A-1.

Licensed Product means any pharmaceutical product including the Compound as its active ingredient the manufacture, use or sale of which would infringe one of the issued, valid unexpired claims or one of the pending claims contained in the Licensor Patent Rights in any country or involves use of the Licensor Know-How.

Field of Use
The field of use is the development of novel anti-atherogenic therapies.

Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque. Initially, there are generally no symptoms. When severe, it can result in coronary artery disease, stroke, peripheral artery disease, or kidney problems, depending on which arteries are affected.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.